James Paul Lang Purchases 321,408 Shares of OptimizeRx Co. (NASDAQ:OPRX) Stock

OptimizeRx Co. (NASDAQ:OPRX) Director James Paul Lang acquired 321,408 shares of OptimizeRx stock in a transaction on Friday, March 14th. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

OptimizeRx Stock Up 2.1 %

OptimizeRx stock opened at $8.79 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $161.92 million, a price-to-earnings ratio of -6.61 and a beta of 1.31. OptimizeRx Co. has a 1-year low of $3.78 and a 1-year high of $14.13. The business has a fifty day moving average price of $5.78 and a 200-day moving average price of $5.94.

Analyst Ratings Changes

Several research firms have commented on OPRX. Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. B. Riley raised OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, Stephens initiated coverage on OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 target price on the stock. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.06.

Hedge Funds Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in OptimizeRx in the 4th quarter worth $25,000. BNP Paribas Financial Markets raised its stake in OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. SG Americas Securities LLC purchased a new position in OptimizeRx in the 4th quarter worth $51,000. Wells Fargo & Company MN raised its stake in OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after acquiring an additional 2,797 shares during the last quarter. Finally, Quest Partners LLC raised its stake in OptimizeRx by 15,965.6% in the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after acquiring an additional 9,739 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.